Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Capital Expenditure for R&D and Infrastructure Expansion
Funding capital expenditure for setting up a new R&D center, Center of Excellence, and corporate infrastructure.
Procurement of Manufacturing Plant and Equipment
Purchasing specialized machinery and equipment to expand manufacturing facilities across Goa and Visakhapatnam.
General Corporate Purposes
Allocating remaining net proceeds for general corporate operational requirements.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Molbio Diagnostics Limited is an Indian medical technology company established in 2000 that specializes in point of care molecular diagnostics. Headquartered in Goa, the company develops, manufactures, and commercializes innovative diagnostic devices and reagent kits designed to deliver accurate medical testing outside centralized laboratory environments. Its flagship platform, Truenat, provides real time quantitative micro-PCR testing for infectious diseases including tuberculosis, COVID-19, hepatitis, and dengue at decentralized point of care settings. The company operates advanced manufacturing facilities and research and development centers across Goa and Visakhapatnam. Supported by more than 100 granted global patents covering microfluidics, diagnostic assays, and portable hardware designs, Molbio has established a commercial distribution network extending to over 80 countries worldwide. This international infrastructure enables healthcare providers in primary health clinics, remote communities, and emergency departments to perform molecular diagnostics efficiently. Molbio Diagnostic operates a high margin razor and blade commercial model, deriving recurring income from initial diagnostic device placements coupled with ongoing sales of single use disease specific assay cartridges. For the fiscal year ended March 31, 2026, the company generated operational revenues of 1,455.17 crore rupees and a net profit after tax of 164.14 crore rupees, maintaining consistent operational expansion driven by portfolio diversification and market adoption.
Molbio Diagnostics raised 281.50 crore rupees by allotting 3,487,000 equity shares at 807 rupees per share to 33 anchor investors on August 7, 2026. Key anchor participants included Goldman Sachs, BlackRock, International Finance Corporation, HDFC Mutual Fund, Nippon India Mutual Fund, ICICI Prudential Mutual Fund, and Kotak Mutual Fund.
Source: RHP • Analysis provided for informational purposes
Last Updated: 17 August 2026, 7:09 AM
Proprietary Point of Care Diagnostic Platform
Market leader with the patented Truenat micro-PCR system, enabling rapid and portable molecular testing across decentralized healthcare settings.
High Margin Razor and Blade Revenue Model
Drives recurring cash flows by pairing initial diagnostic hardware placements with continuous sales of single use disease specific assay cartridges.
Extensive Global Footprint and Intellectual Property
Operates in over 80 countries supported by a global distributor network and more than 100 granted international patents covering microfluidics and molecular reagents.
Revenue Concentration in Truenat Platform
A substantial portion of total operational revenues depends on market demand for the core Truenat hardware and tuberculosis diagnostic kits.
Regulatory Compliance and Patent Protection Dependencies
Global commercial expansion relies on timely multi-jurisdictional regulatory approvals and effective enforcement of proprietary patents against infringement.
Supply Chain Reliance on Specialized Components
Potential disruptions or price escalation in securing microfluidic cartridges, precision microelectronics, or biological reagents could impact production timelines and margins.
Molbio Diagnostics Limited
Plot No. L-46, Phase II-D, Verna Industrial Estate, Verna, Salcete, South Goa - 403 722, Goa, India
View on Maps →No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.